• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向冠状病毒核衣壳蛋白的N端结构域通过变构调节诱导异常寡聚化。

Targeting the N-Terminus Domain of the Coronavirus Nucleocapsid Protein Induces Abnormal Oligomerization via Allosteric Modulation.

作者信息

Hsu Jia-Ning, Chen Jyun-Siao, Lin Shan-Meng, Hong Jhen-Yi, Chen Yi-Jheng, Jeng U-Ser, Luo Shun-Yuan, Hou Ming-Hon

机构信息

Institute of Genomics and Bioinformatics and Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.

Department of Chemistry, National Chung Hsing University, Taichung, Taiwan.

出版信息

Front Mol Biosci. 2022 Apr 19;9:871499. doi: 10.3389/fmolb.2022.871499. eCollection 2022.

DOI:10.3389/fmolb.2022.871499
PMID:35517857
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9061996/
Abstract

Epidemics caused by coronaviruses (CoVs), namely the severe acute respiratory syndrome (SARS) (2003), Middle East respiratory syndrome (MERS) (2012), and coronavirus disease 2019 (COVID-19) (2019), have triggered a global public health emergency. Drug development against CoVs is inherently arduous. The nucleocapsid (N) protein forms an oligomer and facilitates binding with the viral RNA genome, which is critical in the life cycle of the virus. In the current study, we found a potential allosteric site (Site 1) using PARS, an online allosteric site predictor, in the CoV N-N-terminal RNA-binding domain (NTD) to modulate the N protein conformation. We identified 5-hydroxyindole as the lead via molecular docking to target Site 1. We designed and synthesized four 5-hydroxyindole derivatives, named P4-1 to P4-4, based on the pose of 5-hydroxyindole in the docking model complex. Small-angle X-ray scattering (SAXS) data indicate that two 5-hydroxyindole compounds with higher hydrophobic R-groups mediate the binding between N-NTD and N-C-terminal dimerization domain (CTD) and elicit high-order oligomerization of the whole N protein. Furthermore, the crystal structures suggested that these two compounds act on this novel cavity and create a flat surface with higher hydrophobicity, which may mediate the interaction between N-NTD and N-CTD. Taken together, we discovered an allosteric binding pocket targeting small molecules that induces abnormal aggregation of the CoV N protein. These novel concepts will facilitate protein-protein interaction (PPI)-based drug design against various CoVs.

摘要

由冠状病毒(CoV)引起的疫情,即严重急性呼吸综合征(SARS)(2003年)、中东呼吸综合征(MERS)(2012年)和2019冠状病毒病(COVID-19)(2019年),引发了全球公共卫生紧急事件。针对CoV的药物研发本质上十分艰巨。核衣壳(N)蛋白形成寡聚体并促进与病毒RNA基因组的结合,这在病毒的生命周期中至关重要。在本研究中,我们使用在线变构位点预测工具PARS在CoV N端RNA结合结构域(NTD)中发现了一个潜在的变构位点(位点1),以调节N蛋白的构象。我们通过分子对接确定5-羟基吲哚为靶向位点1的先导化合物。基于5-羟基吲哚在对接模型复合物中的姿态,我们设计并合成了四种5-羟基吲哚衍生物,命名为P4-1至P4-4。小角X射线散射(SAXS)数据表明,两种具有较高疏水性R基团的5-羟基吲哚化合物介导了N-NTD与N端二聚化结构域(CTD)之间的结合,并引发了整个N蛋白的高阶寡聚化。此外,晶体结构表明,这两种化合物作用于这个新的空腔并形成一个具有更高疏水性的平面,这可能介导了N-NTD与N-CTD之间的相互作用。综上所述,我们发现了一个靶向小分子的变构结合口袋,其可诱导CoV N蛋白异常聚集。这些新概念将促进针对各种CoV的基于蛋白质-蛋白质相互作用(PPI)的药物设计。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4a1/9061996/9b09a774093a/fmolb-09-871499-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4a1/9061996/d6b361271d63/fmolb-09-871499-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4a1/9061996/b3f54c099e52/fmolb-09-871499-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4a1/9061996/aa8eb0cf16c8/fmolb-09-871499-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4a1/9061996/ecf61c53d425/fmolb-09-871499-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4a1/9061996/8b8aa8799b13/fmolb-09-871499-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4a1/9061996/2b7fdc6f32d3/fmolb-09-871499-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4a1/9061996/9b09a774093a/fmolb-09-871499-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4a1/9061996/d6b361271d63/fmolb-09-871499-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4a1/9061996/b3f54c099e52/fmolb-09-871499-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4a1/9061996/aa8eb0cf16c8/fmolb-09-871499-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4a1/9061996/ecf61c53d425/fmolb-09-871499-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4a1/9061996/8b8aa8799b13/fmolb-09-871499-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4a1/9061996/2b7fdc6f32d3/fmolb-09-871499-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4a1/9061996/9b09a774093a/fmolb-09-871499-g006.jpg

相似文献

1
Targeting the N-Terminus Domain of the Coronavirus Nucleocapsid Protein Induces Abnormal Oligomerization via Allosteric Modulation.靶向冠状病毒核衣壳蛋白的N端结构域通过变构调节诱导异常寡聚化。
Front Mol Biosci. 2022 Apr 19;9:871499. doi: 10.3389/fmolb.2022.871499. eCollection 2022.
2
Targeting protein-protein interaction interfaces with antiviral N protein inhibitor in SARS-CoV-2.靶向 SARS-CoV-2 中的抗病毒 N 蛋白抑制剂与蛋白-蛋白相互作用界面。
Biophys J. 2024 Feb 20;123(4):478-488. doi: 10.1016/j.bpj.2024.01.013. Epub 2024 Jan 17.
3
Current concepts in the development of therapeutics against human and animal coronavirus diseases by targeting NP.通过靶向核蛋白开发抗人类和动物冠状病毒疾病疗法的当前概念
Comput Struct Biotechnol J. 2021;19:1072-1080. doi: 10.1016/j.csbj.2021.01.032. Epub 2021 Jan 30.
4
Antiviral drug design based on structural insights into the N-terminal domain and C-terminal domain of the SARS-CoV-2 nucleocapsid protein.基于对严重急性呼吸综合征冠状病毒2核衣壳蛋白N端结构域和C端结构域的结构洞察进行抗病毒药物设计。
Sci Bull (Beijing). 2022 Nov 30;67(22):2327-2335. doi: 10.1016/j.scib.2022.10.021. Epub 2022 Oct 27.
5
Corrigendum: Targeting the N-terminus domain of the coronavirus nucleocapsid protein induces abnormal oligomerization allosteric modulation.勘误:靶向冠状病毒核衣壳蛋白的N端结构域会诱导异常寡聚化和变构调节。
Front Mol Biosci. 2022 Oct 10;9:1036858. doi: 10.3389/fmolb.2022.1036858. eCollection 2022.
6
MOV10 Helicase Interacts with Coronavirus Nucleocapsid Protein and Has Antiviral Activity.MOV10 解旋酶与冠状病毒核衣壳蛋白相互作用并具有抗病毒活性。
mBio. 2021 Oct 26;12(5):e0131621. doi: 10.1128/mBio.01316-21. Epub 2021 Sep 14.
7
Structural basis for the identification of the N-terminal domain of coronavirus nucleocapsid protein as an antiviral target.冠状病毒核衣壳蛋白 N 端结构域作为抗病毒靶点的鉴定的结构基础。
J Med Chem. 2014 Mar 27;57(6):2247-57. doi: 10.1021/jm500089r. Epub 2014 Mar 12.
8
Potential Coronaviral Inhibitors of the Nucleocapsid Protein Identified In Silico and In Vitro from a Large Natural Product Library.通过计算机模拟和体外实验从大型天然产物库中鉴定出的潜在冠状病毒核衣壳蛋白抑制剂
Pharmaceuticals (Basel). 2022 Aug 24;15(9):1046. doi: 10.3390/ph15091046.
9
Computational drug repurposing study of the RNA binding domain of SARS-CoV-2 nucleocapsid protein with antiviral agents.基于 SARS-CoV-2 核衣壳蛋白 RNA 结合域与抗病毒药物的计算药物再利用研究。
Biotechnol Prog. 2021 Mar;37(2):e3110. doi: 10.1002/btpr.3110. Epub 2020 Dec 30.
10
Structural characterization of the N-terminal part of the MERS-CoV nucleocapsid by X-ray diffraction and small-angle X-ray scattering.通过 X 射线衍射和小角度 X 射线散射对中东呼吸综合征冠状病毒核衣壳 N 端结构的解析。
Acta Crystallogr D Struct Biol. 2016 Feb;72(Pt 2):192-202. doi: 10.1107/S2059798315024328. Epub 2016 Jan 22.

引用本文的文献

1
A colloidal gold immunochromatographic test strip based on mAbs anti-N protein to detect feline coronavirus.一种基于抗N蛋白单克隆抗体的胶体金免疫层析试纸条,用于检测猫冠状病毒。
Microbiol Spectr. 2025 Jul;13(7):e0183024. doi: 10.1128/spectrum.01830-24. Epub 2025 Jun 2.
2
Characterization of the binding features between SARS-CoV-2 5'-proximal transcripts of genomic RNA and nucleocapsid proteins.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)基因组RNA 5'近端转录本与核衣壳蛋白之间结合特征的表征
RNA Biol. 2025 Dec;22(1):1-16. doi: 10.1080/15476286.2025.2471643. Epub 2025 Mar 12.
3
Targeting the receptor binding domain and heparan sulfate binding for antiviral drug development against SARS-CoV-2 variants.

本文引用的文献

1
Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase.新冠病毒聚合酶的 RNA 复制结构基础。
Cell. 2020 Jul 23;182(2):417-428.e13. doi: 10.1016/j.cell.2020.05.034. Epub 2020 May 22.
2
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.一对非竞争的人源中和抗体可阻断 COVID-19 病毒与其受体 ACE2 的结合。
Science. 2020 Jun 12;368(6496):1274-1278. doi: 10.1126/science.abc2241. Epub 2020 May 13.
3
Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19).
针对 SARS-CoV-2 变体的抗病毒药物研发,靶向受体结合域和硫酸乙酰肝素结合。
Sci Rep. 2024 Feb 2;14(1):2753. doi: 10.1038/s41598-024-53111-2.
4
Targeting protein-protein interaction interfaces with antiviral N protein inhibitor in SARS-CoV-2.靶向 SARS-CoV-2 中的抗病毒 N 蛋白抑制剂与蛋白-蛋白相互作用界面。
Biophys J. 2024 Feb 20;123(4):478-488. doi: 10.1016/j.bpj.2024.01.013. Epub 2024 Jan 17.
5
Production of a Monoclonal Antibody to the Nucleocapsid Protein of SARS-CoV-2 and Its Application to ELISA-Based Detection Methods with Broad Specificity by Combined Use of Detector Antibodies.生产针对 SARS-CoV-2 核衣壳蛋白的单克隆抗体,并结合使用检测抗体,在 ELISA 基础检测方法中实现广泛特异性的应用。
Viruses. 2022 Dec 21;15(1):28. doi: 10.3390/v15010028.
6
Small-angle X-ray scattering studies of enzymes.小角 X 射线散射研究酶。
Curr Opin Chem Biol. 2023 Feb;72:102232. doi: 10.1016/j.cbpa.2022.102232. Epub 2022 Nov 30.
7
Computational exploration of the dual role of the phytochemical fortunellin: Antiviral activities against SARS-CoV-2 and immunomodulatory abilities against the host.计算探索植物化学 Fortunellin 的双重作用:抗 SARS-CoV-2 的抗病毒活性和对宿主的免疫调节能力。
Comput Biol Med. 2022 Oct;149:106049. doi: 10.1016/j.compbiomed.2022.106049. Epub 2022 Sep 8.
SARS-CoV-2(COVID-19)的虚拟筛选与抗病毒治疗联合研究。
Microb Pathog. 2020 Sep;146:104241. doi: 10.1016/j.micpath.2020.104241. Epub 2020 May 5.
4
Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.新型冠状病毒主蛋白酶抑制剂卡莫氟的结构基础
Nat Struct Mol Biol. 2020 Jun;27(6):529-532. doi: 10.1038/s41594-020-0440-6. Epub 2020 May 7.
5
Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites.严重急性呼吸综合征冠状病毒2核衣壳蛋白RNA结合结构域的晶体结构揭示了潜在的独特药物靶向位点。
Acta Pharm Sin B. 2020 Jul;10(7):1228-1238. doi: 10.1016/j.apsb.2020.04.009. Epub 2020 Apr 20.
6
5-Hydroxyindole-Based EZH2 Inhibitors Assembled via TCCA-Catalyzed Condensation and Nenitzescu Reactions.基于 5-羟吲哚的 EZH2 抑制剂的 TCCA 催化缩合和内尼采斯库反应构建。
Molecules. 2020 Apr 28;25(9):2059. doi: 10.3390/molecules25092059.
7
Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics.药物研发与药物化学在 SARS-CoV-2 与新冠病毒治疗方面的努力
ChemMedChem. 2020 Jun 4;15(11):907-932. doi: 10.1002/cmdc.202000223. Epub 2020 May 7.
8
Structure of the RNA-dependent RNA polymerase from COVID-19 virus.COVID-19 病毒的依赖 RNA 的 RNA 聚合酶的结构。
Science. 2020 May 15;368(6492):779-782. doi: 10.1126/science.abb7498. Epub 2020 Apr 10.
9
Structure of M from SARS-CoV-2 and discovery of its inhibitors.SARS-CoV-2 M 结构与抑制剂的发现
Nature. 2020 Jun;582(7811):289-293. doi: 10.1038/s41586-020-2223-y. Epub 2020 Apr 9.
10
Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.基于结构的冠状病毒核衣壳蛋白非天然蛋白-蛋白相互作用的稳定化在抗病毒药物设计中的应用。
J Med Chem. 2020 Mar 26;63(6):3131-3141. doi: 10.1021/acs.jmedchem.9b01913. Epub 2020 Mar 11.